FIBROGEN WKN: A12EZ0 ISIN: US31572Q8087 Kürzel: 1FG Forum: Aktien Thema: Hauptdiskussion

Diese Entscheidung solltest du für dich treffen.

👀☕

👀☕

FibroGen Reports Second Quarter 2023 Financial Results https://www.globenewswire.com/news-release/2023/08/07/2720096/33525/en/FibroGen-Reports-Second-Quarter-2023-Financial-Results.html

FibroGen's drug fails late-stage trial for treating lung disease https://www.reuters.com/business/healthcare-pharmaceuticals/fibrogens-lung-disease-treatment-fails-late-stage-trial-2023-06-26/

https://www.globenewswire.com/news-release/2023/06/26/2694309/0/en/FibroGen-Announces-Topline-Results-from-Phase-3-ZEPHYRUS-1-Study-of-Pamrevlumab-for-the-Treatment-of-Idiopathic-Pulmonary-Fibrosis.html

https://www.reuters.com/business/healthcare-pharmaceuticals/fibrogens-neuromuscular-disorder-drug-fails-late-stage-study-2023-06-07/ FibroGen's neuromuscular disorder drug fails in late-stage study

FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia https://investor.fibrogen.com/news-releases/news-release-details/fibrogen-announces-positive-topline-results-china-pivotal-phase • Met primary endpoint of noninferiority of roxadustat to erythropoietin alfa • Plan to file supplemental New Drug Application in China

FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics https://www.globenewswire.com/news-release/2023/05/08/2663795/33525/en/FibroGen-Enters-into-Exclusive-License-for-FOR46-with-Fortis-Therapeutics.html

FibroGen Reports First Quarter 2023 Financial Results https://finance.yahoo.com/news/fibrogen-reports-first-quarter-2023-200100063.html

https://beststocks.com/fibrogen-secures-nondilutive-term-loan-financ/

https://seekingalpha.com/news/3941377-fibrogen-gaap-eps-of-0_70-beats-0_25-revenue-of-34_37m-beats-10_42m FibroGen GAAP EPS of -$0.70 beats by $0.25, revenue of $34.37M beats by $10.42M